Fertility Focus, the fertility technology experts behind OvuSense, a revolutionary, patented product which doubles the chances of conception each month, has achieved record sales and highest ever revenues during the first quarter of 2018.
Of note is the fact that OvuSense is now enjoying a CPA of £34 and a paid conversion rate of 2.19%. Both these figures are way ahead of the company’s forecast for this year (which was CPA £54 and conversion rate 1.00%).
The potential target market for OvuSense is huge, with 12 million women trying to conceive every year. Clinical studies show that around 25% of the total childbearing population suffer from one or more ovulatory issues, which rises to an estimated 70% of the population trying to conceive after six months.
With the goal of increasing pregnancy rates in infertile couples by up to 50%, Fertility Focus brings a brand-new approach to the issue of infertility diagnosis and treatment.
Fertility Focus, a revenue-generating business with a run rate of £1m, has the backing of a leading VCT fund (£1m), the support of an institutional investor (£500k) and £250k already raised from angel groups. It is now seeking the final £200,000 worth of investment to complete the £2m raise in this round at a pre-money valuation of £4.4m.
In a recent webinar with Robert Milnes, CEO of Fertility Focus, Mr Milnes explained in detail the exciting projections for the business. Please click here to see the ‘Live Pitch’ webinar.
If you want to invest in a business that is delivering a high margin SaaS revenue stream, which has serious institutional backing, is EIS eligible, and is transforming the lives of women and their families across the globe, or to learn more, please click here.